People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...

Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...